Fluvastatin lipid-lowering effect in routine practice conditions (FLIRT). Results of a drug surveillance study

Clinical Drug Investigation

Volumn 14, Issue 2, 1997, Pages 146-153

  Beil, Stefan ^a,d   Pfafferott, Conrad ^b   Weber, Michael ^c  

^a Klinikum Schwabing   (Germany)

^b Hospital Ingolstadt   (Germany)

^c Cardiology Department   (Germany)

^d Kreisklinik Dachau   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FLUINDOSTATIN; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTHROPATHY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DRUG EFFECT; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMPOTENCE; INTERNAL MEDICINE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MUSCLE DISEASE; PATIENT SATISFACTION; PRIORITY JOURNAL; SIDE EFFECT; SKIN DISEASE;

EID: 0030825779     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199714020-00009     Document Type: Article

References (25)

1. Statistisches Jahrbuch 1994 für die Bundesrepublik Deutschland. Metzler-Poeschel-Verlag, 1994
2. Wilson PWF, William P, Castelli WP, et al. Coronary risk prediction in adults (The Framingham Heart Study). Am J Cardiol 1987; 59: 91G-94G
3. Castelli WP, Wilson PW, Levy D, et al. Cardiovascular risk factors in the elderly. Am J Cardiol 1989; 63: 12-9
4. Assmann G, Funke H. HDL metabolism and atherosclerosis. J Cardiovasc Pharmacol 1990; 16: 15-20
5. Albrink MJ, Man EB. Serum triglycerides in coronary artery disease. Arch Intern Med 1959; 103: 4-8
6. Germing A, Machraoui A, Poller W, et al. Hypertriglyceridemia as a risk factor for coronary heart disease - an angiographic study. Herz Kreisl 1996; 28: 282-4
7. Manninen V, Huttunen JK, Heinonen OP, et al. Relations between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study. Am J Cardiol 1989; 63: 42-7
8. Holme I. Cholesterol lowering and the reduction of CHD incidence and total mortality: results from a meta-analysis of randomized trials. Cardiovasc Drugs Ther 1992; 6: 101-2
9. Leren P. Prevention of coronary heart disease: some results from the Oslo secondary and primary intervention studies. J Am Coll Nutr 1989; 8 (5): 407-10
10. Brown WV. Review of clinical trials: proving the lipid hypothesis. Eur Heart J 1990; 11 Suppl. H: 15-20
11. Barth JD. Lipoproteins and the progression/regression of atherosclerosis. Baillieres Clin Endocrin Metab 1995; 9 (4): 849-66
12. Farmer JA, Gotto AM Jr. Clinical investigations of the arrest and reversal of coronary artery disease. Coron Artery Dis 1995; 6 (6): 457-65
13. Ratzmann K. Das metabolische Syndrom. Lipid Aktuell 1991; 4(2): 1-8
14. Recommendations of the European Atherosclerosis Society: Prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis 1992; 2: 113-56
15. Baggio G, de Candia O, Forte PL, et al. Efficacy and safety of fluvastatin, a new HMG CoA reductase inhibitor, in elderly hypercholesterolaemic women. Drugs 1994; 47 Suppl. 2: 59-63
16. Milani M, Cimminiello C, Merlo B, et al. Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia. Am J Cardiol 1995; 76 (2): 51A-53A
17. Teramoto T, Goto Y, Kurokawa K, et al. Clinical efficacy of fluvastatin for hyperlipidemia in Japanese patients. Am J Cardiol 1995; 76 (2): 33A-36A
18. Smith JW, Jansen GH, de Bruin TW, et al. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil. Am J Cardiol 1995; 76 (2): 126A-128A
19. Koizumi J, Haraki T, Yagi K, et al. Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia. Am J Cardiol 1995; 76 (2): 47A-50A
20. Peters TK, Muratti EN, Mehra M. Fluvastatin in primary hypercholesterolemia: efficacy and safety in patients at high risk. An analysis of a clinical database. Am J Med 1994; 96 (6A): 79S-83S
21. Leitersdorf E. Gender-related response to fluvastatin in patients with heterozygous familial hypercholesterolaemia. Drugs 1994; 47 Suppl. 2: 54-8
22. Kellick KA, Burns K, McAndrew E. Outcome of fluvastatin in a Department of Veterans Affairs lipid clinic. Am J Cardiol 1995; 76(2): 62A-64A
23. Peters TK, Muratti EN, Mehra M. Efficacy and safety of fluvastatin in women with primary hypercholesterolaemia. Drugs 1994; 47 Suppl. 2: 64-72
24. Peters TK, Mehra M, Muratti EN. Efficacy and safety of fluvastatin in hypertensive patients: an analysis of clinical trial database. Am J Hypertens 1993; 6: 340s-345s
25. Jakubaitis LA. Update clinical safety experience with fluvastatin. Am J Cardiol 1994; 73: 18D-24D